ong-term study of LCZ696 treatment in patients with essential hypertensio
Phase 2
- Conditions
- Essential hypertension
- Registration Number
- JPRN-jRCT2080221787
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 344
Inclusion Criteria
1. Patients that have successfully completed Core study (JapicCTI-101273) and who, as judged by the investigator, are able to continue in the open-label extension.
2. Ability to communicate and comply with all study requirements and demonstrate good medication compliance (>=80% compliance rate) during Core study.
Exclusion Criteria
1. Patients who did not complete Core study.
2. Presence of significant protocol violation in Core study.
3. Patients who are deemed to be unable to comply with the protocol by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method